The EU General Court upholds “novel” approach to abuse of dominance in pivotal pharma appeal (AstraZeneca)

On July 1, 2010, the General Court ruled in an appeal against the European Commission’s first ever finding of abuse of a dominant position by a pharma company. The Court has broadly upheld a Decision the Commission itself characterised as “novel”, but reduced the €60 million fine on AstraZeneca to €52.5 million. Background The judgment marks a watershed in a process that has been running for more than a decade, concerning business practices applied by AstraZeneca between 1993 and 2000. In 1999, following complaints from two generic manufacturers, the Commission opened an investigation into AstraZeneca’s patent management strategies for blockbuster ulcer drug, Losec (omeprazole). The allegations centred around two practices: First, the Commission found that AstraZeneca had engaged in a

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

Citation

Jonas Koponen, Bernd Meyring, Gerwin Van Gerven, The EU General Court upholds “novel” approach to abuse of dominance in pivotal pharma appeal (AstraZeneca), 1er juillet 2010, e-Competitions July 2010, Art. N° 41073

Visites 592

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues